CA2717991A1 - Treatment for ocular-related disorders - Google Patents

Treatment for ocular-related disorders Download PDF

Info

Publication number
CA2717991A1
CA2717991A1 CA2717991A CA2717991A CA2717991A1 CA 2717991 A1 CA2717991 A1 CA 2717991A1 CA 2717991 A CA2717991 A CA 2717991A CA 2717991 A CA2717991 A CA 2717991A CA 2717991 A1 CA2717991 A1 CA 2717991A1
Authority
CA
Canada
Prior art keywords
compound
ocular
agents
patient
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2717991A
Other languages
English (en)
French (fr)
Inventor
Thomas Oligino
Chang Hahn
Timothy A. Gillespy
Ramalinga Dharanipragada
Ellen Matzkin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of CA2717991A1 publication Critical patent/CA2717991A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
CA2717991A 2008-03-10 2009-03-05 Treatment for ocular-related disorders Abandoned CA2717991A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3507308P 2008-03-10 2008-03-10
US61/035,073 2008-03-10
PCT/US2009/036119 WO2009114373A1 (en) 2008-03-10 2009-03-05 Treatment for ocular-related disorders

Publications (1)

Publication Number Publication Date
CA2717991A1 true CA2717991A1 (en) 2009-09-17

Family

ID=40583469

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2717991A Abandoned CA2717991A1 (en) 2008-03-10 2009-03-05 Treatment for ocular-related disorders

Country Status (22)

Country Link
EP (1) EP2285378A1 (es)
JP (1) JP2011513488A (es)
KR (1) KR20110009084A (es)
CN (1) CN101965188A (es)
AR (1) AR070975A1 (es)
AU (1) AU2009223501A1 (es)
BR (1) BRPI0909659A2 (es)
CA (1) CA2717991A1 (es)
CL (1) CL2009000551A1 (es)
CO (1) CO6290691A2 (es)
CR (1) CR11644A (es)
DO (1) DOP2010000266A (es)
IL (1) IL207906A0 (es)
MA (1) MA32211B1 (es)
MX (1) MX2010008308A (es)
NI (1) NI201000131A (es)
NZ (1) NZ587906A (es)
RU (1) RU2010141560A (es)
SV (1) SV2010003658A (es)
TW (1) TW200950784A (es)
WO (1) WO2009114373A1 (es)
ZA (1) ZA201005337B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201034675A (en) 2008-12-18 2010-10-01 Sanofi Aventis Method for treating macular degeneration
EP2441755A1 (en) 2010-09-30 2012-04-18 Almirall, S.A. Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors
EP2489663A1 (en) 2011-02-16 2012-08-22 Almirall, S.A. Compounds as syk kinase inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ301750B6 (cs) * 1999-12-24 2010-06-09 Aventis Pharma Limited Bicyklický pyrrolový derivát, jeho použití pri výrobe léciva, farmaceutická kompozice tento derivát obsahující a pro použití pri lécení
CA2400923A1 (en) * 2000-02-25 2001-08-30 Merck & Co., Inc. Tyrosine kinase inhibitors
KR20140025610A (ko) * 2005-09-30 2014-03-04 미카나 테라퓨틱스, 인크. 치환된 피라졸 화합물
CL2007002617A1 (es) * 2006-09-11 2008-05-16 Sanofi Aventis Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.

Also Published As

Publication number Publication date
RU2010141560A (ru) 2012-04-20
CL2009000551A1 (es) 2009-08-21
CN101965188A (zh) 2011-02-02
MX2010008308A (es) 2010-08-11
SV2010003658A (es) 2011-01-31
AR070975A1 (es) 2010-05-19
ZA201005337B (en) 2011-04-28
MA32211B1 (fr) 2011-04-01
WO2009114373A1 (en) 2009-09-17
IL207906A0 (en) 2010-12-30
AU2009223501A1 (en) 2009-09-17
CR11644A (es) 2010-11-22
NI201000131A (es) 2011-09-29
JP2011513488A (ja) 2011-04-28
NZ587906A (en) 2011-12-22
KR20110009084A (ko) 2011-01-27
DOP2010000266A (es) 2010-09-30
TW200950784A (en) 2009-12-16
BRPI0909659A2 (pt) 2015-09-22
CO6290691A2 (es) 2011-06-20
EP2285378A1 (en) 2011-02-23

Similar Documents

Publication Publication Date Title
JP6608309B2 (ja) Cmt及び関連疾患の処置のための新規な治療的アプローチ
JP5875191B2 (ja) Cmt及び関連障害を処置するための新たな組成物
JP5404045B2 (ja) 神経および非神経痛を治療する方法
KR101663998B1 (ko) 샤르코-마리-투스 질환 및 관련 장애를 치료하기 위한 필로카핀 및 메티마졸 조합
Zhang et al. Inflammatory mechanisms contribute to the neurological manifestations of tuberous sclerosis complex
KR101953736B1 (ko) 제브라피시 모델을 사용한 약물 스크리닝 방법 및 이 방법으로 스크린된 화합물
JPH10236978A (ja) 中枢カンナビノイドレセプターcb1の既知の作用薬の利用
JP2004532809A (ja) ホスホジエステラーゼ4型を阻害することによって、神経系の再生および修復を刺激するための方法
JP2000514402A (ja) Vegfに関連する目の病気に関する治療処置
TW201605443A (zh) 治療x染色體脆折症及相關病症的方法
US20240082312A1 (en) Compositions and methods for williams syndrome (ws) therapy
KR20210081338A (ko) Iv형 콜라겐 질환의 치료를 위한 비페닐 설폰아미드 화합물
JP2021521263A (ja) 眼疾患を治療するための脱メチル化
CA2717991A1 (en) Treatment for ocular-related disorders
Sharif et al. Human trabecular meshwork cells express functional serotonin-2A (5HT2A) receptors: role in IOP reduction
US20110112101A1 (en) Treatment for ocular-related disorders
Lan et al. Sphingosine 1-phosphate receptor agonism impairs skin dendritic cell migration and homing to secondary lymphoid tissue: association with prolonged allograft survival
US20120100229A1 (en) Treatment and Prevention of White Matter Injury with KATP Channel Activators
JP6522641B2 (ja) 機械的な神経損傷を処置するための新規組成物
JP2020519581A (ja) 肥満細胞疾患の処置のための方法及び医薬組成物
WO2024089691A1 (en) Modulators and uses thereof
WO2022217035A1 (en) Activators of integrated stress response pathway for protection against ferroptosis
WO2024100421A1 (en) Sarm1 inhibitors for use in therapy and cosmetics
US20160038521A1 (en) Therapeutic methods

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20130305